Cost-utility analysis of Palbociclib  + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients w...

Source: Health Economics Review - November 9, 2023 Category: Health Management Authors: Ali Darvishi, Rajabali Daroudi and Ali Akbar Fazaeli Tags: Research Source Type: research